



**Date: 23 February 2018**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office  
and**

**Operational Office:**

Suite 3, Level 4

828 Pacific Highway

Gordon NSW 2072

Australia

**Board of Directors**

**Mr Peter Marks**

Chairman

Non-Executive

Director

**Dr Graham Kelly**

Chief Executive Officer

Managing Director

**Dr Ian Dixon**

Non-Executive

Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **HALF YEAR FINANCIAL STATEMENTS - 31 DECEMBER 2017**

**Sydney, 23 February 2018:** Noxopharm Limited (NOX:ASX) is pleased to release its Half Year Financial Statements for the period ended 31 December 2017.

Subsequent to these half year results, as previously announced, the Company has obtained the following funding:

- On 17 January 2018, the Company received \$855,518 through the Federal Government's R&D Rebate Scheme; and
- On 16 February 2018, the Company successfully closed a \$4.0 million capital raising for its US subsidiary, Nyrada Inc.

The Company's primary R&D objectives for the end of the 2017-2018 FY are:

- to have concluded the CEP-1 clinical study and released a full study report on the safety and tumour responses to combination therapy of NOX66 + carboplatin in late-stage cancer patients, and to have announced plans for CEP-2;
- to be well advanced in the recruitment of patients into the LUPIN and DARRT-1 radiotherapy studies, with early clinical data available for review and release by mid-2018;
- to have identified and implemented a clinical strategy for NOX66 in the treatment of adult and paediatric brain cancers;
- to have a fully commissioned NOX66 GMP manufacturing line.

The Company also has the following key objectives for Nyrada, Inc by mid-2018:

- significant pre-clinical progress with NYX-104 as a neuroprotectant drug to protect the brain from stroke, concussion and head trauma;
- pre-clinical evidence confirming the potential of NYX-205 in patients with peripheral neuropathy;
- significant progress in identifying the potential for NYX-330 as an oral drug in the treatment of high blood cholesterol levels.

The Company also is pleased to announce the following recent senior appointments:

- Mr Bhavin Raval has been appointed as Noxopharm Group Chief Financial Officer and Company Secretary (Nyrada).
- Dr John Wilkinson has been appointed Noxopharm Chief Scientific Officer
- Mr James Bonnar has been appointed Vice-President, R&D (Nyrada)
- Mr Mark Waring has been appointed Senior Vice-President, US Operations (Nyrada).

.....

#### **About NOX66**

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. Idronoxil is a kinase inhibitor that works by inhibiting a range of enzymes including sphingosine kinase and PI3 kinase that regulate cell pro-survival mechanisms and which are over-expressed in cancer cells, as well as inhibiting external NADH oxidase Type 2 (ENOX 2) which is responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane of cancer cells and whose expression is limited to cancer cells. Inhibition of these enzymes results in disruption of key downstream prosurvival mechanisms including resistance mechanisms, sensitizing the cancer cell to the cytotoxic effects of chemotherapy drugs and radiotherapies.

#### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

#### **Investor & Corporate Enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### **Company Secretary:**

David Franks  
T: +61 2 9299 9690  
E: [dfranks@fa.com.au](mailto:dfranks@fa.com.au)

[www.noxopharm.com](http://www.noxopharm.com)

#### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.